GGrantIndex
Sort

48,018 grants matching immunotherapy

Mechanisms of Vaccinia Virus Innate Immune Inhibition

$406,250
William Lawrence Marshall · Univ Of Massachusetts Med Sch Worcester · R01 · FY2007 · AI

B Cell Immunity to Hepatitis C Virus

$406,250
Steven Foung · Stanford University · R56 · FY2009 · AI

Engineering the Brain Immune System for Tumor Therapy

$406,250
Maria G Castro · Cedars-Sinai Medical Center · R01 · FY2009 · NS

LncRNA EPIC1 induces immunotherapy resistance by activating EZH2 in breast cancer

$406,248
Da Yang · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA

Oral IFN-tau treatment in RRMS patients

$406,236
Pepgen Corporation · R43 · FY2004 · AI

The role of IL-10 in stabilizing natural regulatory T cells

$406,210
Mitchell Kronenberg · La Jolla Institute For Immunology · P01 · FY2011 · AI

Arenavirus Receptor--Structure/Function Studies

$406,145
Michael B Oldstone · Scripps Research Institute, The · R01 · FY2007 · AI

Arenavirus Receptor-Structure/Function Studies

$406,144
Michael B Oldstone · Scripps Research Institute, The · R01 · FY2009 · AI

IDO1 and Immunotolerance in Glioblastoma

$406,136
Derek Alan Wainwright · Northwestern University At Chicago · R01 · FY2020 · NS

Anti-ceramide immunotherapy for diabetic retinopathy

$406,120
Julia V Busik · Michigan State University · R01 · FY2019 · EY

Immunophysiological Mechanisms in the Biological Therapy of Cancer

$406,116
Robert Wiltrout · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA

Project 2 - Modulation of Anti-Tumor Immunity by Inhibitory Receptors

$406,094
Dario Aa Vignali · University Of Pittsburgh At Pittsburgh · P01 · FY2021 · AI

Balancing protective immunity and chronic sequelae by resident CD8 T cells

$406,068
Jie Sun · Mayo Clinic Rochester · R01 · FY2021 · AI

Project 1: FLASH vs. Standard radiotherapy for treatment of PDAC and sparing normal intestine tissues

$406,043
Constantinos Koumenis · University Of Pennsylvania · P01 · FY2024 · CA

Mechanisms of natural killer cell resistance of treatment-persistent residual tumor cells in hematologic malignancies

$406,038
Constantine S. Mitsiades · Dana-Farber Cancer Inst · R01 · FY2023 · CA

Laboratory and Clinical studies on T-cells recognizing NSCLC

$406,033
James C Yang · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

ST8Sia6 expression on tumors inhibits the immune response

$406,002
Virginia Smith Shapiro · Mayo Clinic Rochester · R01 · FY2020 · CA

Targeting cysteine import to induce ferroptotic cell death in pancreatic cancer

$405,983
Kenneth P Olive · Columbia University Health Sciences · R01 · FY2025 · CA

Mechanisms of Immune Evasion by Hepatitis C Virus

$405,900
Andrea L Cox · Johns Hopkins University · R01 · FY2010 · AI

CHILDRENS CANCER GROUP

$405,880
Children'S Hospital Of Philadelphia · U10 · FY2002 · CA

Single-cell and imaging data integration software to spatially resolve the tumor microenvironment

$405,874
Elana Fertig · Johns Hopkins University · U01 · FY2020 · CA

HSV-1 TK MODIFIED T CELLS FOR GRAFT VERSUS LEUKEMIA

$405,860
University Of Pennsylvania · P50 · FY2000 · HL

Analysis of peripheral tolerance in vivo

$405,856
Marc K. Jenkins · University Of Minnesota · P01 · FY2014 · AI

Analysis of peripheral tolerance in vivo

$405,856
Marc K. Jenkins · University Of Minnesota · P01 · FY2013 · AI

Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications

$405,748
Birgit Knoechel · Dana-Farber Cancer Inst · R01 · FY2021 · CA